Given her history and today's findings, what should I consider next?

AKAnna Keller, 47 · Hypertension, prediabetes, LDL 162 mg/dl · 14 documents, read 16 September 2026

Answered on 16 September 2026

Practice guidelineEuropean Society of Cardiology

ESC 2021: in apparently healthy people under 50, SCORE2 estimates the 10-year risk; risk modifiers such as a family history of premature cardiovascular disease, lipoprotein(a) and coronary artery calcium can move a patient across a treatment threshold. At low-to-moderate risk, lipid-lowering treatment should be considered when LDL cholesterol stays at or above 100 mg/dl after lifestyle intervention. Eur Heart J

European Society of Cardiology

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.

Visseren FLJ, Mach F, Smulders YM, et al. European Heart Journal. 2021;42:3227-3337. doi:10.1093/eurheartj/ehab484.

Her SCORE2 (moderate-risk region, 47 years, non-smoker now, systolic 142, non-HDL 186 mg/dl) is about 3 %, low to moderate for her age. Check-up 12.05.2026 Lab 08.05.2026 Eur Heart J Three modifiers push upward: her father's infarction at 58, an LDL of 162 mg/dl and prediabetes with steatosis. Intake 20.09.2023 Lab 08.05.2026 Ultrasound 12.05.2026

Lipids: statin rechallenge with atorvastatin 10 mg or rosuvastatin 5 mg, LDL target below 100 mg/dl, lipids, ALT and CK after eight weeks; lipoprotein(a) once with the next draw. Eur Heart J + 2
Blood pressure: home mean 136/86 is above the ESC 2024 target of 120 to 129 systolic; increase ramipril to 10 mg, potassium and creatinine after two weeks, home log again in four weeks. BP log 15.09.2026 Eur Heart J
Prediabetes and liver: structured lifestyle programme (the Diabetes Prevention Program reduced diabetes incidence by 58 %), HbA1c in three to six months, FIB-4 from the May values. NEJM J Hepatol
Optional risk refinement: a coronary calcium scan if she or you want more certainty before committing to long-term treatment. Eur Heart J

Today's draft note already lists the statin start, the ramipril increase and the booster; the FIB-4 and the lifestyle programme are not yet in it. Visit 16.09.2026

From the patient record6 of 14 documents

Check-up (Gesundheitsuntersuchung) documentation, SCORE2, 12 May 2026Check-up
Laboratory report, 8 May 2026Laboratory
Intake interview, history and family history, 20 September 2023Anamnesis
Abdominal ultrasound report, 12 May 2026Imaging
Home blood pressure log, 9 to 15 September, 15 September 2026Patient data
Visit note, today's consultation (draft), 16 September 2026Clinical note

1.2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.European Heart Journal. 2021;42:3227-3337. Visseren FLJ, Mach F, Smulders YM, et al.Guideline
SummaryRisk estimation with SCORE2 (40 to 69 years) and SCORE2-OP; risk modifiers include a family history of premature cardiovascular disease, lipoprotein(a), coronary artery calcium and psychosocial stress. In apparently healthy people at low-to-moderate risk, lipid-lowering treatment should be considered when LDL cholesterol stays at or above 2.6 mmol/l (100 mg/dl) after lifestyle intervention; a stepwise approach with treatment targets by risk category.
Source
Issuing body: European Society of Cardiology
Published: September 2021
Grading system: ESC classes of recommendation I–III, levels of evidence A–C
Scope
Target population: Apparently healthy people and patients with established disease
Scope: Risk assessment, lifestyle, lipids, blood pressure, diabetes
2.SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe.European Heart Journal. 2021;42:2439-2454. SCORE2 working group and ESC Cardiovascular risk collaboration.Trial
3.2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.European Heart Journal. 2020;41:111-188. Mach F, Baigent C, Catapano AL, et al.Guideline
SummaryLDL cholesterol goals by risk category: below 116 mg/dl at low risk, below 100 mg/dl at moderate risk, below 70 mg/dl at high risk, below 55 mg/dl at very high risk. Statins first, ezetimibe second, PCSK9 inhibitors third. Statin interactions run mainly through CYP3A4 (atorvastatin, simvastatin) and OATP1B1; monitoring of ALT and CK is defined.
Source
Issuing body: ESC and European Atherosclerosis Society
Published: January 2020; focused update 2025
Grading system: ESC classes of recommendation I–III, levels of evidence A–C
Scope
Target population: Adults with dyslipidaemia or elevated cardiovascular risk
Scope: Targets, drugs, monitoring, special situations
4.Statin-associated muscle symptoms: impact on statin therapy. European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management.European Heart Journal. 2015;36:1012-1022. Stroes ES, Thompson PD, Corsini A, et al.Guideline
SummaryDefines statin-associated muscle symptoms as symmetric proximal muscle pain, weakness or stiffness beginning within weeks to months of a statin start and improving within weeks of withdrawal; CK is usually normal or mildly raised. Management: withdraw, wait for symptoms to resolve, then rechallenge with the same or a different statin at a lower dose or alternate-day dosing; most patients tolerate a second statin. Non-statin therapy for those who cannot.
Source
Issuing body: European Atherosclerosis Society Consensus Panel
Published: May 2015
Grading system: Consensus statement
Scope
Target population: Patients with muscle symptoms on statin therapy
Scope: Definition, assessment, management, rechallenge
5.Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.European Heart Journal. 2022;43:3925-3946. Kronenberg F, Mora S, Stroes ESG, et al.Guideline
6.2024 ESC Guidelines for the management of elevated blood pressure and hypertension.European Heart Journal. 2024;45:3912-4018. McEvoy JW, McCarthy CP, Bruno RM, et al.Guideline
SummaryIntroduces the category “elevated blood pressure” (120 to 139/70 to 89 mmHg) and recommends a treated systolic target of 120 to 129 mmHg for most adults if tolerated. Home blood pressure monitoring is recommended to confirm the diagnosis and guide treatment: seated after five minutes of rest, two readings morning and evening for at least three, ideally seven days. Combination therapy is preferred when one drug is insufficient.
Source
Issuing body: European Society of Cardiology
Published: August 2024
Grading system: ESC classes of recommendation I–III, levels of evidence A–C
Scope
Target population: Adults with elevated blood pressure or hypertension
Scope: Diagnosis, targets, lifestyle, drug therapy, monitoring
7.Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.The New England Journal of Medicine. 2002;346:393-403. Knowler WC, Barrett-Connor E, Fowler SE, et al.Trial
8.EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).Journal of Hepatology. 2024;81:492-542. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity.Guideline
SummarySteatotic liver disease with at least one cardiometabolic risk factor is MASLD. In primary care, patients with steatosis or metabolic risk should have non-invasive fibrosis assessment with FIB-4: below 1.3 rules out advanced fibrosis with repeat testing in one to three years; 1.3 or above calls for elastography or referral. Treatment is weight reduction, physical activity and control of the metabolic risk factors.
Source
Issuing body: EASL, EASD, EASO
Published: September 2024
Grading system: GRADE
Scope
Target population: Adults with steatotic liver disease and metabolic risk factors
Scope: Case finding, fibrosis assessment, management

What would you like to ask next?

1What does the current guideline recommend as her blood pressure target?2Draft a patient plan from today's decision 3Create a take-home explaining why she is starting a statin

This is a sample workspace. Click one of the questions. To ask your own questions, request access.

Anna Keller, 47Mosaic